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Abstract
XIAP-associated factor 1 (Xaf1) binds XIAP and re-localizes it to the nucleus, thus inhibiting XIAP activity and enhancing
apoptosis [1]. Xaf1 expression is reduced or absent in tumor samples and cell lines suggesting it may function as a tumor
suppressor [2–5]. To further study Xaf1 function we generated Xaf1 inducible cells in the osteosarcoma cell line Saos-2. Despite
Xaf1 inducing apoptosis that is dramatically enhanced by TNFα we find no evidence for an interaction between Xaf1 and XIAP.
Furthermore, Xaf1 expression sensitized XIAP−/− fibroblasts to TNFα, demonstrating the existence of a novel mechanism of
Xaf1 induced apoptosis distinct from antagonizing XIAP. Xaf1 expression promotes cytochrome c release that cannot be blocked
by inhibition of caspase activity. This implicates a role for the mitochondrial apoptotic pathway, consistent with the ability of
Bcl2 to block Xaf1 induced apoptosis. The data indicate that in Saos2 cells Xaf1 activates the mitochondrial apoptotic pathway
to facilitate cytochrome c release, thus amplifying apoptotic signals from death receptors. (Mol Cell Biochem 286: 67–76, 2006)
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Introduction
Apoptosis is an evolutionarily conserved form of cell death,
which plays critical roles during development, differentiation
and tissue homeostasis of multi-cellular organisms. Defects
in apoptosis play an important role in the pathogenesis of a
number of diseases including cancer, neurodegenerative and
auto-immune diseases [6]. Central mediators of the apoptotic
process are the caspases. These proteases are synthesized as
zymogens that are activated by either an increase in local
concentration or by cleavage by other caspases (or in some
cases non-caspase proteases) [7]. This can lead to a cascade
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of caspase activation, eventually mediating the orderly de-
struction of the cell [7, 8].
Two major pathways of apoptosis are described as the death
receptor (or extrinsic) and the mitochondrial (or intrinsic). In
both pathways apical initiator caspases are activated which
in turn activate other caspases. The extrinsic pathway is ac-
tivated by ligation of death receptors such as Fas and Tu-
mor Necrosis Factor Receptor (TNFR) with their appropri-
ate ligand. This results in the formation of a signaling com-
plex activating caspase 8 [9]. The intrinsic or mitochondrial
pathway is regulated by members of the Bcl2 family, which
either promote or inhibit apoptosis [10, 11]. This pathway
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can be activated by a variety of stresses including radiation
and chemotherapeutic agents resulting in the release of cy-
tochrome c and other pro-apoptotic molecules from the mi-
tochondria into the cytosol. Cytochrome c binds to Apaf1
forming a macromolecular structure termed the apoptosome
that recruits and activates caspase 9 [12].
Apoptosis is regulated post activation of caspases, by the
inhibitor of apoptosis proteins (IAPs), that bind and inhibit
the activity of caspases [13]. In many experimental systems,
the X-linked inhibitor of apoptosis (XIAP) is the most po-
tent of the IAPs, binding and inhibiting the activity of several
caspases, notably caspases 3, 7 and 9 [14, 15]. In addition
to the activation of caspases, efficient induction of apop-
tosis requires relief of IAP-mediated caspase inhibition. A
number of proteins that bind and antagonize IAP function
have been identified including the mitochondrial sequestered
SMAC/Diablo and HtrA2/Omi [16, 17]. These proteins are
released from the mitochondria in response to apoptotic sig-
nals and inhibit IAP function.
In addition to these mitochondrial sequestered proteins,
other proteins have been identified that can modulate XIAP
activity, including Xaf1. Xaf1 was isolated as an XIAP in-
teracting protein in a yeast 2-hybrid screen and antago-
nizes XIAP caspase inhibition by direct interaction and re-
localization of XIAP from cytosol to the nucleus [1, 18]. Xaf1
expression has been found to be reduced or absent in multiple
tumor cell lines, in comparison to normal cells [4]. In addi-
tion, expression is lost in a subset of gastric, melanoma and
colon cancer samples, suggesting that Xaf1 may function as
a tumor suppressor [2, 3, 5].
To further investigate Xaf1 function we generated Xaf1
inducible Saos-2 cell lines. Doxycycline treatment results in
accumulation of Xaf1 in the nucleus and apoptosis that is en-
hanced by treatment with other inducers of apoptosis, most
dramatically TNFα. Despite Xaf1 promoting apoptosis in this
cell line, XIAP remains in the cytosol, and we see no evidence
of an interaction between these proteins. In addition, expres-
sion of Xaf1 in XIAP null fibroblasts renders these cells sensi-
tive to TNFα treatment, demonstrating a XIAP-independent
function of Xaf1. Furthermore we demonstrate that Xaf1 can
induce apoptosis by activation of the mitochondrial pathway,
promoting cytochrome c release that cannot be inhibited by
the caspase inhibitor z-VAD. Our data reveal the existence
of a previously unidentified function of Xaf1 in facilitating
cytochrome c release to enhance apoptosis by other signals.
Materials and methods
Transfection and cell culture
Saos-2 cells and mouse fibroblasts were maintained in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 2 mM L-glutamine (Cellgro),
100 U/ml penicillin and streptomycin (Cellgro). For trans-
fections, 5 × 105 cells were transfected with 10 μg of expres-
sion plasmid and 2 μg of pCMV CD20 expression plasmid
by calcium phosphate precipitation. Xaf1 inducibles were
generated using methods previously described [19, 20]. Par-
allel transfections allowed isolation of Xaf1 inducibles and
cells containing only the empty vector as controls. The cells
were maintained in Dulbecco’s Modified Eagle’s Medium
supplemented with 10% fetal bovine serum (Tet System Ap-
proved FBS, BD Biosciences), 2 mM L-glutamine (Cellgro),
100 U/ml penicillin and streptomycin (Cellgro).
Immunoprecipitations and immunoblotting
Cells were harvested in Cell Lysis Buffer (20 mM Tris pH
7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Tri-
ton X100 and complete proteinase inhibitors). Cellular de-
bris was removed by centrifugation at 13000 g at 4◦C for
10 minutes. For immunoprecipitations, the cell lysates were
pre-cleared with 20 μl of protein A-sepharose beads in Cell
Lysis Buffer (Pierce, 20398), and then incubated with appro-
priate antibodies at 4◦C for 2 hours, followed by addition
of 20 μl protein A-Sepharose beads and incubation at 4◦C
for 30 minutes. Immunoprecipitates were washed 4 times
with Cell Lysis Buffer and once with PBS. Bound proteins
were eluted and resolved by SDS-PAGE, and transferred
to PVDF membranes (Hybond-P, Amersham). Membranes
were blocked in TBST containing 5% skimmed milk, and
then incubated for 2 hours with specific antibodies (anti-Flag
M2 (Sigma, F3165), anti-GFP JL-8 (Clontech, 8371-2), anti-
HA F-7 (Santa Cruz, E289), anti-actin (Sigma, A2066), anti-
Xaf1 (IMGENEX, IMG-379), and anti-XIAP (Stressgen,
AAM-50). The membranes were then washed, and incubated
for 1 hour with horseradish peroxidase (HRP)-conjugated
anti-mouse or anti-rabbit antibodies (Amersham Biosciences,
NA931V/NA934V). Visualization of protein bands was ac-
complished using enhanced chemiluminescence (Amersham
Biosciences) according to the manufacturer’s instructions.
Immunofluorescence microscopy
Cells grown on cover slips were fixed in 4% paraformalde-
hyde for 10 minutes at room temperature, rinsed three times in
PBS, permeabilized with cold 0.2% TritonX-100/PBS for 5
minutes, and then blocked for 2 hours (3% BSA and 10%
FBS in PBS) at room temperature. Cells were incubated
with various antibodies (anti-HA F-7 Santa Cruz E289, anti-
HILP/XIAP BD Transduction Laboratories 610763, at 1:200
dilution) for 2 hours at room temperature, rinsed three times
in PBS, and then incubated with anti-mouse Alexa 488 or
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anti-rat Alexa 594 (Molecular Probes, A11008/A11007)
1:200 for 1 hour at room temperature. Cells were then washed,
and stained with DAPI (30 nM) for 10 min at room tempera-
ture prior to mounting on glass slides using anti-fade (Molec-
ular Probes).
DNA content analysis
Saos-Xaf1 inducible cells (3 × 105) were treated as indi-
cated with doxycycline (Fisher, 2 μg/ml), TNFα (Endogen,
2 ng/ml), CHX (Fisher, cycloheximide, 4 μg/ml) Apo2L/
Trail (Cellsciences, 4 μg/ml), Z-VAD-fmk (CalBiochem,
50 μM) and Adriamycin (Sigma, 2 μg/ml). Floating and at-
tached cells were collected, pooled washed in PBS and fixed
with methanol for 2 hours at 4◦C. The cells were washed in
PBS and re-suspended in PBS supplemented with propidium
iodide (Fisher, 50 μg/ml) and RNAse A (Sigma, 50 μg/ml).
DNA content was assessed by flow cytometry as previously
described [20], and cells with less than 2N DNA content are
scored as apoptotic. Apoptosis in transfected cells is mea-
sured in the same manner, with identification of transfected
cell by co-transfection of a CD20 expression plasmid and
staining as previously described [20].
Cell fractionation
Cells (1 × 106) were isolated by trypsinization. The cell pel-
lets were washed in ice cold PBS and re-suspended in 200 μl
buffer A (10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and complete
proteinase inhibitor (Calbiochem), and incubated on ice for
15 minutes. After addition of 12.5 μl 10% NP-40, the pellets
were vortexed for 15 seconds and spun at 13000 rpm 1 minute
at 4◦C in a microfuge. Supernatants containing cytoplasmic
protein were collected. The pellets were washed 3 times with
buffer A, vortexed for 15 min after addition of 30 μl buffer C
(20 mM Hepes (pH 7.9), 420 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 1mM PMSF and proteinase inhibitors)
centrifuged 13000 rpm for 5 min at 4◦C. The supernatant
containing nuclear proteins was collected [21]. The nuclear
and cytoplasmic fractions were resolved by SDS PAGE and
analyzed by western blot.
Cytochrome c flow cytometery assay
Cells (2 × 105) were collected by trypsinization, rinsed in
PBS, and incubated in 200 μl digitonin solution (digitonin
50 μg/ml (Calbiochem), 100 mM KCl in PBS) on ice for
5 min. Cells were fixed using 500 μl of 4% paraformadehyde
at room temperature for 20 minutes. Cells were washed three
times in PBS, blocked for 1 hour in 500 μl blocking buffer
(3% BSA, 0.05% Saponin (Sigma) in PBS), followed by incu-
bation with anti-cytochrome c antibody 1:200 (Pharmingen,
6H2.B4) overnight at 4◦C. Cells were washed three times
with PBS and incubated for 1 hour in 50 μl of anti-Ig-FITC
(DAKO, F0479) diluted 1:10 in PBS. The cells were rinsed in
PBS, and re-suspended in 400 μl of PBS containing RNAse
A (50 μg/ml) and propidium iodine (50 μg/ml) and incubated
at room temperature for 1 hour. Measurement of DNA con-
tent was assessed in FL2 and cytochrome c fluorescence was
measured in FL1 using a Becton Dickenson FACScalibur.
Results
Xaf1 induces apoptosis in Saos-2 cells
We established HA-Xaf1 inducible cell lines in the human
osteosarcoma tumor cell line Saos-2. Five clones that were
capable of significant induction of Xaf1 in response to doxy-
cycline treatment were analyzed in initial experiments, and
compared to clones containing only empty vector. Treatment
of empty vector controls demonstrated no effect of doxy-
cycline on the growth or apoptosis of Saos2 cells (data not
shown). All Xaf1 clones behaved in a similar fashion, and
the results from a typical clone are presented. Treatment of
doxycycline results in accumulation of detectable levels of
Xaf1 by 8 hours and as previously reported (Fig. 1A),Xaf1
is located throughout the nucleus [1], however, we also see
predominant staining in sub-nuclear spots that have the ap-
pearance of nucleoli (Fig. 1B).
To determine if Xaf1 expression modulates cell cycle dis-
tribution and/or induces apoptosis in Saos2 cells, Xaf1 was
induced and DNA content was measured by propidium iodide
staining and flow cytometry (Fig. 1C and D). Apoptotic cells
(those with less than 2N DNA content) begin accumulating at
12 hours after doxycycline treatment and increase to around
20–25% at 24 hours. In contrast, no significant effect on the
cell cycle distribution is seen, with the small changes in pro-
portion of cells in G1, S, and G2/M most likely an indirect
consequence of the loss of cells by apoptosis.
Xaf1 cooperates with TNFα in the induction of apoptosis
XIAP is a broad specificity inhibitor of apoptosis, blocking
cell death induced by both the death receptor and mitochon-
drial apoptotic pathways by direct interaction with caspases
[13]. Relief of XIAP inhibition of caspase activity by Xaf1
expression would be predicted to cooperate with multiple in-
ducers of apoptosis. This is supported by work from other in-
vestigators, indicating that Xaf1 enhances apoptosis induced
by a variety of agents [1, 18].
70
Fig. 1. Xaf1 induces apoptosis. Xaf1 tetracycline inducible cell lines were generated in Saos-2 cells. (A) Western blot showing accumulation of Xaf1 after
addition of doxycycline for the times indicated. (B) Immunofluorescence of cells treated (where indicated) with doxycycline for 18 hours. Cells are stained
with anti-HA (Xaf1 Green) and DAPI (Blue). (C) Flow cytometric profiles showing DNA content (x-axis) against cell number (y-axis) for Xaf1 inducible
cells treated with doxycycline for the times indicated in the figure. (D) Average percentage of apoptotic cells (cells with less than 2N DNA content scored as
apoptotic) after doxycycline treatment for the times indicated in the figure.
We tested if Xaf1 expression cooperated with the death
receptor ligands TNFα and Apo2L/TRAIL in the induction
of apoptosis in Saos-2 cells. Low levels of TNFα do not in-
duce apoptosis in Saos-2 cells (2 ng/ml) [22], however, in
combination with the inhibition of protein synthesis, these
cells undergo dramatic apoptosis indicating the presence of
functional receptors (Fig. 2A and 2B).In the Xaf1 inducible
cell lines, treatment with TNFα induces around 10% apopto-
sis in the absence of doxycycline treatment (level in parental
Saos2 and control lines is 2–3%) and this is increased to 50%
after induction of Xaf1 for 24 hours. This rate of apoptosis
is sufficient to eliminate almost all of the cells in culture.
The observation that Xaf1 clones have increased sensitiv-
ity to apoptosis compared to the empty vector controls in
the absence of doxycycline is presumably a consequence of
some ‘leakiness’ in the system, suggesting that low levels
of Xaf1 undetectable by western blot inhibit cell survival.
In contrast to TNFα, this level of Apo2L/TRAIL does not
significantly cooperate with Xaf1 in the induction of apopto-
sis, even though inhibition of protein synthesis was capable
of rendering these cells extremely sensitive to this ligand
(Fig. 2A and 2B). Increasing levels of Apo2L leads to an in-
duction of apoptosis that was enhanced by Xaf1 expression,
although the cooperation was not as dramatic as with TNFα
(data not shown).
Xaf1 expression rendered Saos2 cells sensitive to UV in-
duced apoptosis. In contrast, Adriamycin was unable to coop-
erate with Xaf1 in the induction of apoptosis. Despite Adri-
amycin inducing significant apoptosis alone, expression of
Xaf1 did not increase the level of apoptosis (Fig. 2A and 2B).
XIAP independent function of Xaf1
To determine if the synergy between Xaf1 and TNFα was a
consequence of an inhibition of XIAP function we first deter-
mined if these proteins were co-localized in the cell. Xaf1 is
a nuclear protein and can re-localize XIAP from the cytosol
to the nucleus [1]. In absence of doxycycline treatment, the
sub-cellular localization of XIAP was determined to be in the
cytosol, with staining typical for that seen in other cell types
for this IAP. Induction of Xaf1 expression did not change the
localization or staining pattern of XIAP (Fig. 3A).To confirm
these results and obtain a more quantitative measure of the
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Fig. 2. Xaf1 cooperates with TNFα in the induction of apoptosis. (A) Flow cytometric profiles showing DNA content (x-axis) against cell number (y-axis) for
Xaf1 inducible cells treated with doxycycline (DOX), cycloheximide (CHX), TNFα, Apo2L, Adriamycin and UV as indicated as indicated in the figure. The
number in each box indicates percentage of apoptotic cells. (B) Average levels of apoptosis for Xaf1 inducible cells treated with the agents indicated in the
Fig., with (solid bar) and without (hatched) doxycycline treatment.
location of Xaf1 and XIAP we treated the Xaf1 inducible
cells with doxycycline, TNFα and doxycycline and TNFα
together and fractionated the cells. Total cell extract indi-
cates that the levels of XIAP are unchanged by either Xaf1
expression or Xaf1 and TNFα treatment in combination (Fig.
3B). Comparison of the nuclear and cytoplasmic fractions in-
dicated that almost all detectable XIAP is in the cytosol and
all almost all Xaf1 is in the nucleus (Fig. 3C). Even under
conditions where Xaf1 is dramatically enhancing TNFα in-
duced apoptosis, Xaf1 and XIAP are not co-localized.
One concern may be that in the generation of the lines,
there may have been selection against cells in which Xaf1
and XIAP co-localized, since Xaf1 reduced colony formation
relative to empty vector control plasmid. To test this, we tran-
siently expressed HA-Xaf1 and Flag-XIAP in the parental
Saos-2 cells, and performed immuno-precipitation to deter-
mine if there was any detectable interaction in this cell type.
No interaction could be detected, nor can any co-localization
be seen (Fig. 3D and data not shown).
These experiments provide strong evidence that Xaf1 is
inducing apoptosis independently of XIAP. However, it is
possible that a small fraction of total Xaf1 is sufficient to
inhibit XIAP function in the cytosol. To eliminate this pos-
sibility we utilized fibroblasts derived from XIAP deficient
mice [23]. These cells were transfected with Xaf1 and con-
trol vector expression constructs and treated with TNFα for
24 hours. Transfected cells were identified by staining pos-
itive for the transfection marker CD20, and apoptosis was
assessed by measuring DNA content. Xaf1 expression in-
creased the sensitivity of these fibroblasts to TNFα (Fig. 3E),
clearly demonstrating a XIAP independent function of Xaf1.
Xaf1 and Xaf1+TNFα induced apoptosis require activation
of the mitochondrial pathway
Although for convenience the death receptor and mitochon-
drial pathways are described separately, many cells require
amplification of the apoptotic signal generated by death re-
ceptors through activation of the intrinsic pathway [24]. In
some cell types this linking of the pathways is provided
by the caspase 8 mediated cleavage of the BH3-only pro-
tein BID, this cleaved form translocates to the mitochondria
triggering mitochondrial outer membrane permeabilization
(MOMP) and release of cytochrome c [25, 26]. To deter-
mine if there is a requirement for activation of the mito-
chondrial apoptotic pathway for Xaf1 or Xaf1 and TNFα
in combination to induce apoptosis, we transiently trans-
fected the Xaf1 inducibles with Bcl2 expression constructs.
The cells were treated with doxycycline, TNFα or both as
indicated (Fig. 4),and apoptosis was assessed in the trans-
fected population. Baculovirus p35 was utilized as a positive
control, functioning as a broad specificity caspase inhibitor
[27], and inhibited apoptosis induced by both Xaf1 expres-
sion and Xaf1 and TNFα in combination. Expression of Bcl2
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Fig. 3. XIAP independent function of Xaf1 (A) Immunofluorescence of cells treated (as indicated) with doxycycline for 18 hours. In the top three panels, cells
are stained with anti-HA (Xaf1 Green) or anti-XIAP and DAPI (Blue). In the lower three panels cells are stained with anti-XIAP (Green) or anti-XIAP and DAPI
(Blue). (B) Western blot showing XIAP levels after treatment with doxycycline, TNFα, doxycycline and TNFα for 24 hours. (C) Xaf1 inducible cells were
treated with doxycycline, TNFα, doxycycline and TNFα for 24 hours as indicated in the figure. Western blot showing the levels of Xaf1 and XIAP in the nuclear
and cytoplasmic fractions. Successful separation of nuclear and cytoplasmic fractions is verified by blotting for GAPDH (cytoplasmic) and C23 (nuclear). (D)
Extracts of Saos2 cells transfected with plasmids encoding Flag-XIAP and HA-Xaf1 as indicated were immuno-precipitated with α-Flag and immuno-blotted
with α-HA and α-Flag as indicated. Lower panel is a western blot using extract corresponding to 10% of protein used in the immuno-precipitation. (E) XIAP−/−
mouse fibroblasts were transiently transfected with plasmids driving expression of Xaf1 or control empty vector and pCMV-CD20. The cells were treated with
TNFα(20 ng/ml) for 24 hours, and apoptosis was measured by flow cytometry (those cells with less than 2N DNA content are scored as apoptotic). The graph
expresses the average apoptotic rate for cells expressing CD20.
also inhibited all apoptosis triggered by Xaf1, and Xaf1 and
TNFα in combination demonstrating that the apoptosis in-
duced by Xaf1 requires engagement of the mitochondrial
apoptotic pathway (Fig. 4).
Xaf1 triggers cytochrome c release
Bcl2 inhibition of Xaf1 induced apoptosis indicates a require-
ment for activation of the mitochondrial pathway. Although
activation of the mitochondrial pathway by death receptors
is caspase dependent, activation of this pathway can occur
in a caspase independent manner. For example p53 induces
expression of the BH3 only proteins PUMA and Noxa that
antagonize Bcl2 function, promoting cytochrome c release
[28, 29]. If Xaf1 is functioning only to relieve IAP medi-
ated repression of caspase activity, then we would predict
that caspase activity would be necessary for the Xaf1 medi-
ated engagement of the mitochondrial pathway, leading to the
release of cytochrome c and other pro-apoptotic molecules.
By use of the pan-caspase inhibitor z-VAD, we can determine
if caspase activity is necessary for the release of cytochrome
c from the mitochondria.
As a quantitative measure of cytochrome c release we uti-
lized flow cytometry. Digitonin permeabilization of the cell
membrane allows cytochrome c that is not retained in the mi-
tochondria to be leached out of the cell [30]. By minor modi-
fication of this protocol, we could measure DNA content and
cytochrome c fluorescence on the same cells, allowing us to
demonstrate the effectiveness of z-VAD caspase inhibition.
Since DNA fragmentation is dependent on caspase activity,
z-VAD blocks DNA fragmentation even if cytochrome c has
been released from the mitochondria. We treated the cells
with doxycycline for 18 hours and measured cytochrome
c release and DNA content. As a control we treated cells
with cycloheximide (CHX) and TNFα, as this results in a
caspase dependent release of cytochrome c. Xaf1 expres-
sion triggered cytochrome c release, as more dramatically
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Fig. 4. Bcl2 inhibits Xaf1 induced apoptosis. The Xaf1 inducible cells
were transiently transfected with p35, Bcl2 or control empty vector expres-
sion plasmids and pCMV-CD20. The cells were treated with doxycycline
(2 μg/ml), TNFα(2 ng/ml), or TNFα and doxycycline 24 hours and apoptosis
was measured by flow cytometry. The graph expresses the average apoptotic
rate for cells expressing CD20.
did Xaf1+TNFα and CHX+TNFα treatment (Fig. 5A and
B).Addition of z-VAD efficiently blocked cytochrome c re-
lease of the CHX+TNFα treated cells, in contrast the Xaf1
mediated release of cytochrome c was unaffected by z-VAD
treatment (Fig. 5A and B). However, z-VAD treatment re-
sulted in complete inhibition of Xaf1 mediated DNA frag-
mentation, indicating successful inhibition of caspase activity
Fig. 5. Xaf1 triggers cytochrome c release by a caspase independent mechanism. The effect of z-VAD on Xaf1 induced apoptosis and cytochrome c release
was measured by flow cytometry. Xaf1 inducible cells were treated as indicated with doxycycline, TNFα, CHX, and z-VAD for 24 hours. (A) Flow cytometric
profiles showing log cytochrome c fluorescence (x-axis) and cell number (y-axis). (B) Average percentage of cells with less than 2N DNA content (apoptotic),
and percentage of cells with released cytochrome c. (C) The results after normalization, showing relative inhibition of DNA fragmentation and cytochrome c
release in the presence of z-VAD.
by z-VAD (Fig. 5B). Although TNFα and CHX induced dra-
matic release of cytochrome c, this was fully inhibited by
z-VAD (Fig. 5C shows the results normalized, indicating al-
most 100% inhibition of cytochrome c release for TNFα and
CHX treatment).
Treatment of cells with doxycycline and TNFα generates
a similar level of DNA fragmentation and cytochrome c re-
lease as TNFα+CHX. In contrast although z-VAD treatment
blocked DNA fragmentation efficiently, cytochrome c release
was only partially blocked. This result is what we would pre-
dict as although TNFα promotes cytochrome c release by a
caspase dependent mechanism, Xaf1 mediated cytochrome c
release was not blocked by z-VAD. This data suggests that
Xaf1 facilitates cytochrome c release independently of cas-
pase activation, indicating that Xaf1 has apoptotic properties
in addition to the relief of XIAP-mediated (or other IAP)
caspase inhibition.
Discussion
We extended previous findings indicating that Xaf1 can
cooperate with a number of agents in the induction of
apoptosis to Saos2 cells. Xaf1 cooperated with both TNFα
and Apo2L/TRAIL, although more dramatically with TNFα
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(Fig. 2 and data not shown). UV irradiation induced apop-
tosis was also enhanced by Xaf1 expression, however the
chemotherapeutic drug Adriamycin was unable to cooper-
ate with Xaf1, despite being capable of inducing apoptosis
alone. The reason for the differences is unclear but may be
related to the apoptotic pathways these agents stimulate, with
Xaf1 perhaps cooperating more efficiently with death recep-
tor signaling. Although UV can activate the mitochondrial
apoptotic pathway [31–33], in some cell types UV can cross
link the Fas receptor and TNFR1, independently of their lig-
ands [34, 35]. However, further work is required to determine
if Xaf1 cooperation is limited to agents activating death re-
ceptor signaling, and why Xaf1 cooperates more efficiently
with TNFα than Apo2L/TRAIL.
Cooperation between Xaf1 and death receptors such as
TNFR could occur at a number of levels. XIAP can inhibit
apoptosis upstream of MOMP in response to death receptor
signaling, by preventing full processing of caspase 3 [36].
Expression of Xaf1 would be predicted to neutralize XIAP
repression of caspases thus enhancing death receptor induced
apoptosis. Although work from other investigators indicates
that that Xaf1 can function in this manner in some cell types
[1, 18], the data here show no evidence for a Xaf1-XIAP
interaction in Saos2 cells. Furthermore Xaf1 was able to sen-
sitize XIAP−/− fibroblasts to TNFα, indicating that Xaf1 can
promote apoptosis independently of XIAP (Fig. 6).
Fig. 6. Xaf1 can regulate apoptosis upstream and downstream of caspase
activation. The model illustrates the points in the apoptotic cascade that Xaf1
can function. In addition to binding to XIAP reported by other investigators
[1], our data demonstrate that Xaf1 can stimulate apoptosis by promoting
the release of cytochrome c in a caspase independent manner.
Further studies are required to determine what signals con-
trol the interaction of Xaf1 and XIAP and the sub-cellular
localization of these proteins, as well as the functional con-
sequences. In addition to our data showing no co-localization,
Leaman et al. have shown that interferon induced induction
of Xaf1 results in Xaf1 accumulation in both nucleus and
cytoplasm, however XIAP remains cytoplasmic [18]. XIAP
has been reported in the nucleus in a number of papers, and
interestingly can relocate from the cytosol to the nucleus in
response to a number of stress signals [37–40]. Clearly in
different cell types and/or under different conditions these
proteins can locate to different sub-cellular compartments.
An interesting possibility is that in response to certain stress
conditions XIAP relocates to the nucleus to antagonize Xaf1
function, rather that Xaf1 antagonizing XIAP.
An obligatory role for the mitochondrial pathway in Xaf1
induced apoptosis is supported by the ability of Xaf1 alone
to promote cytochrome c release, which cannot be inhib-
ited by z-VAD. This data suggests that in Saos2 cells Xaf1
does not induce apoptosis by relief of IAP-mediated caspase
inhibition. Further support for a role for the mitochondrial
pathway in Xaf1 induced apoptosis is provided by our data
demonstrating that Bcl2 can block Xaf1 induced apoptosis.
Our data implicate Xaf1 as functioning upstream of the mi-
tochondria in a caspase independent manner. All of the data
are consistent with a role in facilitating cytochrome c release
from mitochondria to amplify apoptotic signals. This may
explain, at least in part, why Xaf1 cooperates with death re-
ceptor ligands such as TNFα, but not Adriamycin which itself
can activate the mitochondrial apoptotic pathway.
How Xaf1 promotes cytochrome c release independently
of caspase activation is unclear. A direct role at the mito-
chondria seems unlikely since almost all detectable Xaf1 is
in the nucleus. However, since Bcl2 can inhibit Xaf1 induced
apoptosis it is possible that the mechanism could involve the
modulation of the level, activity, or location of BH family
protein(s). A large family of Bcl2 related proteins exist in-
cluding proteins that inhibit or induce apoptosis including
certain BH3 only proteins that play key roles in activating
this apoptotic pathway by antagonizing Bcl2-like proteins
[28, 29, 41, 42]. Since Xaf1 expression is lost in a variety of
tumor types and may function as a tumor suppressor further
experiments to determine how Xaf1 induces apoptosis are
warranted [2, 3, 5].
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